Watch Brent's inspiring story and how Signatera testing helped him stay ahead in his fight against bladder cancer. We're proud to share stories like Brent's to inspire and showcase the power of personalized cancer monitoring. 💪💛 #BladderCancerAwareness #Signatera #Natera #CancerSurvivor #SurvivorStrong See the full story: https://ow.ly/Pl1F50SbRYE
Natera Oncology
Biotechnology Research
Austin, TX 14,865 followers
Transforming the management of cancer with personalized ctDNA testing.
About us
Signatera is a personalized, tumor-informed assay optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with cancer. Follow us on Twitter: @NateraOncology
- Website
-
https://www.natera.com/oncology/signatera-advanced-cancer-detection
External link for Natera Oncology
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Austin, TX
- Founded
- 2004
- Specialties
- oncology, cancer, colorectal cancer, circulating tumor dna, breast cancer, bladder cancer, and immunotherapy
Updates
-
Now published: Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma in The Oncologist Journal. Key takeaways: 📈 ctDNA detection during the MRD window (2-12 weeks post-surgery, before adjuvant therapy): 29% (29/100). 📈 ctDNA detection during post-treatment surveillance window: 29.6% (45/152). 📈 ctDNA-positivity during the MRD or surveillance windows was significantly associated with shorter disease-free survival (MRD window: HR: 5.45, P < .0001; surveillance window: HR: 12.38, P < .0001). 📈 In multivariate analysis, ctDNA detection at surveillance was found to be the most significant prognostic factor for recurrence (HR: 24.28, P < .001). See the full study here: https://ow.ly/5cqt50SHCq5
-
Karen Zaghiyan, MD, FACS, FASCRS explains how she uses Natera's Signatera test in her clinical practice for colorectal cancer patient management. See the video on our website: https://ow.ly/mPpq50SEJO7 #ctDNA
-
Natera Oncology reposted this
Catch my latest chat with Theral Timpson of Mendelspod where I discuss how I ventured into the world of ctDNA what we know so far and what the future holds for Signatera in Colorectal cancer. Natera Oncology
Adham Jurdi was a practicing oncologist during the pandemic. He soon saw that Natera's ctDNA test was predicting what would happen with his patients several months before the scans would show anything and decided to use it across the board with his patients. Then he joined Natera to help shape the field. Listen to his interview here: https://lnkd.in/g7QGQaRD
The Success of ctDNA Testing in Colorectal Cancer: Adham Jurdi, Natera
mendelspod.com
-
What does survivorship mean to you? 💛 "Survivorship to me means that I belong to a group of people that approach life in a different way and never take things for granted. It means you are not contagious but you are informational. We accept the bad days, the challenging days and the good days and approach things with a positive outlook. It means that you are able to see your daughter or son graduate high school and go to college like me, it means you get to meet your new baby nephew like me, it means you get to live life and not take a single day for granted – like me!" - Angela, breast cancer survivor and clinical oncology specialist at Natera Thank you, Angela, for sharing your perspective on survivorship, reflecting on family and community. #Natera #SurvivorMonth #SurvivorStrong Angela Devine
-
📣 We are excited to announce a new gastroesophageal cancer trial, DECIPHER, that will utilize Natera's personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to guide patient selection and assess the rate of MRD clearance in patients being treated for gastroesophageal cancer. “With an adaptive approach aimed at eliminating MRD, DECIPHER is designed to offer patients a second chance at a cure when they have not responded to standard of care therapies,” said Dr. Elizabeth Smyth, M.D., consultant in medical oncology at Oxford University Hospitals NHS Foundation Trust l and chief investigator of the trial. “Signatera’s personalized, tumor-informed approach, which has demonstrated high sensitivity across several different cancer types including EGC, will be a key component of this study.” Read more in the press release below. #Natera #Signatera #CancerResearch https://ow.ly/Z1BE50SqRRA
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
-
What does survivorship mean to you? 💛 "To me, survivorship means more time with my family, friends and colleagues. It means victory, success and a healthy/happy life with a "second chance." Survivorship is a blessing that brings a unique perspective to life and the gift of each and every day. My message to those who are currently battling cancer or beginning their survivorship journey would be to advocate for yourself, fight for what you want and what you feel is right. Never give up." – Jacob Hall, appendiceal cancer survivor, associate clinical oncology specialist for Natera Thank you, Jacob for sharing this powerful reminder! #TeamNatera #SurvivorStrong #Natera
-
"Signatera gave me a nine month head start." | Hear how Brent's oncology team used Signatera testing to help him stay ahead in his fight against bladder cancer. We're proud to share stories like Brent's and showcase the power of personalized cancer monitoring. 💪💛 #BladderCancerAwareness #Signatera #Natera #CancerSurvivor #SurvivorStrong See the full story: https://ow.ly/W98h50SbIuJ
-
Team Natera is still soaking up all that ✨ magic ✨ from our weekend at #CampBreastie. We were honored to be part of this incredible event, which hosted over 600 breast and gynecological cancer survivors from across the continent for a weekend of learning, bonding, and growing stronger – together. From the heartfelt dialogues with Breasties at our Natera booth to the inspiring "You Have Options" panel discussion featuring esteemed experts and advocates, we learned and shared so much. This panel included Natera's sr. medical science liaison Janie Fielder, MSN, RN, who shared how Signatera MRD testing can be used to help inform treatment decisions in breast cancer. Thank you to each and every Breastie who stopped by and shared their story with us. You can watch a recording of the "You Have Options" panel here: https://ow.ly/6BoF50Sh6QW #YoungBreastCancer #YoungOvarianCancer #SurvivorStrong #Signatera #WAHTMM #Breasties Kelly Mellott Dina Scaglione
-
What does survivorship mean to you? 💛 "To me, survivorship means being able to be there for all the moments — from bedtime snuggles, pre-k graduation and a princess-filled trip to Disney. I wish people knew that the hard part often comes after treatment ends. The unknowns of whether the cancer will return, losing friends to cancer, and grieving your life before cancer is challenging. To those battling cancer and just beginning the survivorship journey, make friends with others within your cancer community. I don’t know what I would have done without the support of my two breast friends." - Dana, breast cancer survivor We're thankful for the courage from our community members like Dana, who inspire us with their reflection on their healthcare journey. #CancerSurvivorMonth #SurvivorStrong #BreastCancerSurvivor